Cellectis Kiemelkedően
Mi az Cellectis Kiemelkedően?
A Kiemelkedően az Cellectis - 72.094M
Mi a Kiemelkedően meghatározása?
A fennálló részvények egy olyan vállalat vagy pénzügyi eszköz részvényei, amelyeket a befektetők engedélyeztek, bocsátottak ki és vásároltak meg.
Shares outstanding includes all stock held by investors including both common shares held by the public and restricted shares owned by the company's internal managements. Shares outstanding have rights and represent an ownership in the corporation by the person who holds the shares. They are distinguished from treasury shares, which are shares held by the corporation itself and have no exercisable rights. Shares outstanding plus treasury shares together amount to the number of issued shares.
Shares outstanding can be calculated as either basic or fully diluted. The basic count is the current number of shares. Dividend distributions and voting in the general meeting of shareholders are calculated according to this number. The fully diluted shares outstanding count, on the other hand, includes diluting securities, such as warrants, capital notes or convertibles. If the company has any diluting securities, this indicates the potential future increased number of shares outstanding. A company's market capitalization is calculated by multiplying the price of one of its shares by the total number outstanding shares a company has issued.
Kiemelkedően a Health Care szektor a NASDAQ-on cégekben a Cellectis -hoz képest
Mit csinál Cellectis?
cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene editing – built on its flagship talen® technology and pioneering electroporation system pulseagile – cellectis uses the power of the immune system to target and eradicate cancer cells. using its life-science-focused, pioneering genome engineering technologies, cellectis’ goal is to create innovative products in multiple fields and with various target markets. cellectis is listed on the nasdaq market (ticker: clls) and on the nyse alternext market (ticker: alcls). to find out more about us, visit our website: www.cellectis.com talking about gene editing? we do it. talen® is a registered trademark owned by the cellectis group.
kiemelkedően -hoz hasonló cégek Cellectis
- Shanghai MicroPort Endovascular MedTech Co nak Kiemelkedően 71.978M van
- BlackRock Municipal Income Fund Inc nak Kiemelkedően 71.992M van
- Triple nak Kiemelkedően 71.996M van
- Satin Creditcare Network nak Kiemelkedően 72.020M van
- Global Net Lease nak Kiemelkedően 72.025M van
- Stockmann Oyj Abp nak Kiemelkedően 72.049M van
- Cellectis nak Kiemelkedően 72.094M van
- Cloud DX nak Kiemelkedően 72.094M van
- Bioasis Technologies nak Kiemelkedően 72.144M van
- Urban Exposure Plc nak Kiemelkedően 72.156M van
- Titan International nak Kiemelkedően 72.159M van
- BGR Systems nak Kiemelkedően 72.162M van
- BGR Systems nak Kiemelkedően 72.162M van